Physician profile
Donna Moss
NPI 1396023453
$4,187.71
in general payments reported to CMS, 2019-2025
35 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,148 · 2022: $1,110 · 2023: $1,030 · 2024: $734 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,929.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,119.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $595.67 | 2021-2024 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $508.98 | 2021-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $358.15 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $159.25 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $158.25 | 2021-2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $152.91 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $132.97 | 2022-2023 | Stelara, Remicade, Simponi Aria |
| Gilead Sciences, INC. | $111.71 | 2021-2024 | |
| Pfizer INC. | $108.94 | 2021-2024 | |
| Amgen INC. | $72.30 | 2022-2023 | Amjevita, Avsola |
| Merck Sharp & Dohme LLC | $68.37 | 2021-2023 | Dificid |
| Ardelyx, INC. | $62.31 | 2022-2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $55.58 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $48.11 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $42.75 | 2021 | |
| Novo Nordisk INC | $38.10 | 2023-2024 | Wegovy |
| Ferring Pharmaceuticals INC. | $37.42 | 2024 | Rebyota |
| Qol Medical, LLC | $33.64 | 2021 | |
| Fresenius Kabi USA, LLC | $33.47 | 2023-2024 | Idacio |
| Aimmune Therapeutics, INC. | $33.24 | 2024 | |
| Organon LLC | $27.59 | 2021-2023 | Renflexis |
| Evoke Pharma, INC. | $26.35 | 2021-2023 | Gimoti |
| Ipsen Biopharmaceuticals, INC | $23.64 | 2024 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $19.82 | 2022 | |
| Boston Scientific Corporation | $19.20 | 2023 | Watchman Access System |
| Redhill Biopharma INC. | $19.08 | 2022 | |
| Nestle Healthcare Nutrition INC. | $18.64 | 2023 | |
| Blueprint Medicines Corporation | $16.57 | 2023 | Ayvakit |
| Shield Therapeutics INC | $16.56 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.24 | 2023 | Cyltezo |
| Lilly USA, LLC | $14.95 | 2023 | |
| Sandoz INC. | $13.30 | 2022 | |
| Celgene Corporation | $13.02 | 2022 | |
| Braintree Laboratories, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.